Oppenheimer & Co. Inc. purchased a new stake in ARK Genomic Revolution ETF (BATS:ARKG – Free Report) during the third quarter, Holdings Channel reports. The institutional investor purchased 30,016 shares of the company’s stock, valued at approximately $1,627,000.
Several other hedge funds have also recently added to or reduced their stakes in the company. Baird Financial Group Inc. lifted its position in shares of ARK Genomic Revolution ETF by 0.3% during the 2nd quarter. Baird Financial Group Inc. now owns 73,722 shares of the company’s stock worth $3,101,000 after buying an additional 255 shares during the last quarter. Farther Finance Advisors LLC boosted its stake in shares of ARK Genomic Revolution ETF by 22.2% during the third quarter. Farther Finance Advisors LLC now owns 1,914 shares of the company’s stock worth $104,000 after buying an additional 348 shares during the period. PNC Financial Services Group Inc. raised its position in ARK Genomic Revolution ETF by 53.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,088 shares of the company’s stock worth $29,000 after buying an additional 378 shares during the last quarter. GK Wealth Management LLC purchased a new stake in shares of ARK Genomic Revolution ETF during the 3rd quarter worth $27,000. Finally, Private Advisor Group LLC boosted its position in ARK Genomic Revolution ETF by 2.9% during the first quarter. Private Advisor Group LLC now owns 21,144 shares of the company’s stock worth $559,000 after purchasing an additional 605 shares in the last quarter.
ARK Genomic Revolution ETF Stock Performance
BATS:ARKG opened at $51.40 on Monday. The company’s 50-day moving average is $49.92 and its two-hundred day moving average is $37.37. ARK Genomic Revolution ETF has a 12-month low of $24.60 and a 12-month high of $58.83.
ARK Genomic Revolution ETF Profile
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.
Featured Stories
- Five stocks we like better than ARK Genomic Revolution ETF
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
Want to see what other hedge funds are holding ARKG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARK Genomic Revolution ETF (BATS:ARKG – Free Report).
Receive News & Ratings for ARK Genomic Revolution ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARK Genomic Revolution ETF and related companies with MarketBeat.com's FREE daily email newsletter.
